LICENSEE’S PERFORMANCE. 4.1 The Licensee agrees to meet the performance development milestones attached as Schedule B hereto. The Licensee further agrees to use reasonable commercial efforts to monitor on a worldwide basis patent infringement regarding any Patent Rights licensed under this Agreement;
LICENSEE’S PERFORMANCE. Nothing in this Article 19 will restrict, limit, waive, or excuse LICENSEE’s performance of any other obligations set forth elsewhere in this AGREEMENT.
LICENSEE’S PERFORMANCE. LICENSEE agrees to carry out the plan for development and marketing of a licensed invention submitted with LICENSEE's application for license dated to bring this licensed invention to practical application by (date) , and LICENSEE will, thereafter, continue to make the benefits of this licensed invention reasonably accessible to the public for the remainder of the duration of this LICENSE. LICENSEE agrees that during the duration of this LICENSE any products embodying this licensed invention or produced through the use of the licensed invention for use or sale by LICENSEE or its sublicensees in the United States will be manufactured substantially in the United States. LICENSEE shall pay to the LICENSOR a non-refundable licensing fee in the amount of dollars ($ ) payable upon the execution of this LICENSE by LICENSEE. LICENSEE agrees to pay to LICENSOR one half of any licensing fee collected from any sublicensee. Payment will be made in the manner prescribed in Article IV. LICENSEE agrees to report promptly to LICENSOR any changes in mailing address, name or company affiliation during the period of this LICENSE and to report promptly discontinuance of LICENSEE's making the benefits of this licensed invention reasonably accessible to the United States public.
LICENSEE’S PERFORMANCE. 5.1 LICENSEE agrees that during the period of this LICENSE any products embodying a LICENSED INVENTION or produced through the use of a LICENSED INVENTION for use or sale by LICENSEE or its SUB-LICENSEES in the UNITED STATES will be manufactured substantially in the UNITED STATES. Upon request of LICENSEE or any SUB-LICENSEE, LICENSORS agree to reasonably cooperate with LICENSEE or such SUB-LICENSEE to obtain a waiver of this requirement from the UNITED STATES government, and, in the event such waiver is obtained, LICENSORS will be deemed to have waived the obligations of this Section 5.1.
LICENSEE’S PERFORMANCE. LICENSEE agrees to carry out the Commercial Development Plan (Appendix C) for development and marketing of a Licensed Invention submitted with LICENSEE’S “Application for License” dated 16 June 2016 to bring a Licensed Invention to Practical Application consistent with the milestones provided in the Commercial Development Plan by 31 December 2022; and LICENSEE will, thereafter, continue to make the benefits of a Licensed Invention reasonably accessible to the public for the remainder of the period of this LICENSE. LICENSEE agrees that during the period of this LICENSE any products embodying a Licensed Invention or produced through the use of a Licensed Invention for use or sale in the United States will be manufactured substantially in the United States. LICENSEE agrees to promptly report to LICENSOR any changes in mailing address, name or company affiliation during the period of this LICENSE and to promptly report discontinuance of LICENSEE’S making the benefits of this Licensed Invention reasonably accessible to the United States public. LICENSEE agrees to supply the Navy, at no charge, one (1) display article of a Royalty-Bearing Product that is made, used or sold by or on behalf of LICENSEE or SUBLICENSEE, within 60 days of the first commercial sale of such Royalty-Bearing Products, sent to the address specified in Article 11. LICENSEE shall continue to supply one (1) display example of each distinct product line every third year thereafter for the duration of the Agreement.
LICENSEE’S PERFORMANCE. LICENSEE agrees to carry out the plan for development and marketing of the licensed invention submitted with LICENSEE's Application for License dated to bring the licensed invention to practical application by (date) and LICENSEE will, thereafter, continue to make the benefits of the licensed invention reasonably accessible to the public for the remainder of this LICENSE. LICENSEE agrees that during the period of this LICENSE any products embodying the licensed invention or produced through the use of a licensed invention for use or sale in the United States will be manufactured substantially in the United States. LICENSEE shall pay to the LICENSOR a nonrefundable licensing fee in the amount of dollars ($ ) payable upon the execution of this LICENSE by LICENSEE. Payment will be made in the manner prescribed in Article IV. LICENSEE agrees to promptly report to LICENSOR any changes in mailing address, name or company affiliation during the period of this LICENSE and to promptly report discontinuance of LICENSEE'S making the benefits of this licensed invention reasonably accessible to the United States public.
LICENSEE’S PERFORMANCE. 10 Article IV Royalties.............................. 11 Article V Sublicensing........................... 14 Article VI
LICENSEE’S PERFORMANCE. All of the covenants and obligations that LICENSEE is required to perform or to comply with pursuant to this Agreement at or prior to the Closing (considered collectively), and each of these covenants and obligations (considered individually), shall have been performed and complied with in all material respects.
LICENSEE’S PERFORMANCE. 3.1 LICENSEE agrees to exercise commercially reasonable diligence to carry out the COMMERCIAL DEVELOPMENT PLAN to bring one or more LICENSED INVENTION to PRACTICAL APPLICATION by October 1, 2009. LICENSEE will, thereafter, continue to make the benefits of the LICENSED INVENTIONS reasonably accessible to the public for the remainder of the period of the LICENSE.
LICENSEE’S PERFORMANCE. LICENSEE agrees to carry out the plan for development and marketing of the LICENSED INVENTIONS submitted with LICENSEE’S application for license dated June 28, 1996 to bring these LICENSED INVENTIONS to practical application as soon as commercially feasible, and LICENSEE will, thereafter, continue to make the benefits of these LICENSED INVENTIONS reasonably accessible to the public for the remainder of the period of this LICENSE. LICENSEE agrees to spend not less than One Million Dollars ($1,000,000) per year, either internally or through AFFILIATES or SUBLICENSEES or other collaborators, on the research, development and marketing (and associated costs related thereto) of products in the [*], CTLA4 and/or B7 immune modulation area, which area includes, without limitation, the LICENSED INVENTIONS. LICENSEE agrees that during the period of this LICENSE any products embodying these LICENSED INVENTIONS or produced through the use of the LICENSED INVENTIONS for use or sale by LICENSEE or its AFFILIATES or SUBLICENSEES in the UNITED STATES will be manufactured substantially in the UNITED STATES. LICENSEE shall pay to the LICENSOR a non-refundable licensing fee in the amount of ONE HUNDRED THOUSAND DOLLARS ($100,000) payable, at the LICENSOR’s election, either: (a) upon the execution of this LICENSE by LICENSEE or (b) at a later date during the term of this ‘LICENSE, upon ninety (90) days prior written notice to LICENSEE. LICENSEE agrees to pay to LICENSOR [*] of any sublicensing fee (other than running royalty payments or research and development reimbursements for research and/or development performed after the effective date of the applicable sublicense agreement) collected from any SUBLICENSEE. If LICENSEE is required to pay a portion of such sublicensing fee to a third party (other than the. University of Michigan (“MICHIGAN”) pursuant to a May 28, 1992 License Agreement, as amended, between MICHIGAN and GI’s predecessor in interest under such License Agreement, Repligen Corporation), then [*] of LICENSEE’S payments to such third party shall be deducted [*] Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. from the portion of the sublicensing fee payable to LICENSOR. However, in no event shall LICENSOR’S share of any sublicensing fee be reduced below [*]. Payment will be made in the manner prescribed in Article IV. L...
